Healthcare News | BioTuesdays by Kilmer Lucas IR

Developments

iBio expands collaboration with AzarGen to develop plant-made rituximab

iBio (NYSE AMERICAN:IBIO) advanced its collaboration with closely-held AzarGen Biotechnologies by initiating development of a plant-made rituximab for the South African market. iBio previously used its FastPharming...

September 17, 2019

Developments

Concert Pharma completes enrollment in second open label alopecia areata trial

Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its second open label trial comparing once-daily versus twice-daily dosing of CTP-543, a deuterium-modified ruxolitinib, in alopecia areata patients...

September 17, 2019

Markets

SVB Leerink starts Axonics Modulation at OP; PT $45

SVB Leerink initiated coverage of Axonics Modulation Technologies (NASDAQ:AXNX) with an “outperform” rating and $45 price target. The stock closed at $30.27 on Sept. 16. “To us, Axonics represents a hyper-growth story...

September 17, 2019

Markets

TBIG starts Cellular Biomedicine at buy; PT $19

TBIG launched coverage of Cellular Biomedicine Group (NASDAQ:CBMG) with a “buy” rating and $19 price target. The stock closed at $14.84 on Sept. 16. Cellular has been developing its cGMP grade cell therapy manufacturing...

September 17, 2019

Markets

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

H.C. Wainwright raised its price target for Pluristem Therapeutics (NASDAQ:PSTI) to $15.50 from $3.50, reflecting a 10-for-1 reverse stock split and promising early results from a Phase 1 study. The stock closed at $4...

September 17, 2019

Markets

Dawson James starts BioCardia at buy; PT $24

Dawson James Securities launched coverage of BioCardia (NASDAQ:BCDA) with a “buy” rating and $24 price target. The stock closed at $4.84 on Sept. 16. BioCardia is a developing two different cell therapy systems to...

September 17, 2019

Developments

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

Allena Pharmaceuticals (NASDAQ:ALNA) has completed enrollment in the first of two Phase 3 clinical trials of reloxaliase for the treatment of enteric hyperoxaluria. Enteric hyperoxaluria occurs when an underlying...

September 16, 2019

Developments

FDA AdCom votes to approve Aimmune’s PALFORZIA for peanut allergy

An advisory committee of the FDA voted to support the use of Aimmune Therapeutics’ (NASDAQ:AIMT) PALFORZIA in children and teens with peanut allergy. The committee voted seven-to-two that the efficacy data and eight-to...

September 16, 2019

Developments

Bellerophon gets FDA orphan drug designation for IPF therapy

Bellerophon Therapeutics (NASDAQ:BLPH) received FDA orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF) with nitric oxide. IPF is a progressive and fatal lung disease caused by the...

September 16, 2019

Developments

Verrica Pharma submits NDA for molluscum contagiosum drug

Verrica Pharmaceuticals (NASDAQ:VRCA) submitted an NDA to the FDA for its molluscum contagiosum drug candidate, VP-102. Molluscum contagiosum is a viral skin infection that currently has no FDA-approved therapies. VP...

September 16, 2019

Developments

Wave Life Sciences gets FDA fast track designation for suvodirsen

Wave Life Sciences (NASDAQ:WVE) received FDA fast track designation for suvodirsen for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder caused by the absence of dystrophin – a protein that...

September 16, 2019

Developments

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

TG Therapeutics (NASDAQ:TGTX) presented initial Phase 3 and updated Phase 2 data for ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (RMS). At the 35th Annual...

September 13, 2019

iBio expands collaboration with AzarGen to develop plant-made rituximab

Concert Pharma completes enrollment in second open label alopecia areata trial

SVB Leerink starts Axonics Modulation at OP; PT $45

TBIG starts Cellular Biomedicine at buy; PT $19

HCW ups Pluristem PT to $15.50 from $3.50 post reverse split

Dawson James starts BioCardia at buy; PT $24

Allena Pharma completes enrollment in first of two Phase 3 enteric hyperoxaluria trials

FDA AdCom votes to approve Aimmune’s PALFORZIA for peanut allergy

Bellerophon gets FDA orphan drug designation for IPF therapy

Verrica Pharma submits NDA for molluscum contagiosum drug

Wave Life Sciences gets FDA fast track designation for suvodirsen

TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab

General

More